Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Psoriasis in Women - Insights on Disease Impact, Treatment Options, and Gender Differences
Description
The presentation discusses psoriasis, focusing on its impact on women, particularly during pregnancy, and highlights the differences in disease burden and treatment responses between genders. Psoriasis, affecting 60 to 125 million people globally, shows equal prevalence in men and women but a higher quality of life burden in women. Evidence suggests that women with psoriasis are more likely to experience depression, which increases to 21% during pregnancy. Moreover, pregnant women with moderate to severe psoriasis face adverse outcomes, including lower birth rates and neonatal complications. The presentation emphasizes the importance of managing psoriasis effectively prior to pregnancy to mitigate these risks. It also covers gender differences in treatment response, where women generally respond better to therapies, though they may face higher side effects. It concludes by calling for better understanding and collaboration on treatment guidelines and research studies to improve psoriasis care, especially concerning gender and pregnancy-related challenges.
View moreConclusions
- Psoriasis is a chronic inflammatory skin disease affecting millions worldwide and has no gender prevalence differences.
- Women with psoriasis experience a higher disease-related burden compared to men, despite having higher severity indices in males.
- Depression is prevalent among psoriasis patients, particularly elevated during pregnancy, with up to 21% of pregnant women affected.
- Women with moderate to severe psoriasis tend to have fewer children, impacting birth rates in comparison to the general population.
- During pregnancy, 60% of psoriasis patients have skin improvement, but post-partum, 65% report worsening of symptoms.
- Psoriasis is identified as an independent risk factor for negative pregnancy outcomes, including low birth weight and preterm birth.
- Appropriate treatment management before and during pregnancy is crucial for women with psoriasis to mitigate risks.
- Research indicates that women's expectations and treatment responses are higher than men's, but they also face greater side effects.
- Current treatment guidelines suggest that cyclosporine and UV therapy are safer options during pregnancy, with restrictions on biologic use.
- The ongoing global healthcare study aims to enhance understanding and accessibility of psoriasis treatment, especially focusing on gender differences.
- Maul JT et al. JEADV 2018
- Griffiths et al. 2007
- Parisi et al. 2020
- Augustin et al. 2010
- Simon M et al. Biologika und konventionelle Systemtherapien in PsoBest: Outcomes syst. Psoriasistherapien der Routineversorgung: 14. Deutscher Kongress für Versorgungsforschung, Berlin, 7.-9.10.2015
- McDonough E et al. J Rheumatol. 2014;41(5):887-896
- Bandoli G et al. Br J Dermatol. 2010;163(2):334-349
- Lesuis N et al. Gender and the treatment of immune-mediated chronic inflammatory diseases: RA, IBD and PSO: an observational study, BMC Med. 2012;10:82
- Gonzalez-Cantero A et al. Br J Dermatol. 2019
- Cather JC et al. J Am Acad Dermatol 2012
- Murase JE et al. Arch Dermatol. 2005.
- Chiou et al. Arthritis Rheumatol. 2017; Bröms et al. Acta Derm Venereol. 2018; Gulliver et al. Glob Dermatol. 2015; Yang et al. J Am Acad Dermatol. 2011; Porter et al. Int J Womens Dermatol. 2017
- Klein, S., Flanagan, K. Sex differences in immune responses. Nat Rev Immunol
- Maul et al. JEADV 2018, Maul JT et al. BJD 2021, Guillet C ... Maul JT et al. Int J of Women's Derm. 2022
- Maul JT et al. Dermatology 2020
- Flint J et al. Rheumatology. 2016; Götestam Skorpen C et al. Ann Rheum Dis. 2016
- Nast A ... Maul JT ... Dressler C. JEADV 2020
- Fabio Verardi ... JT Maul JEADV 2023
- Maul et al. BJD 2023